271 related articles for article (PubMed ID: 17537288)
1. Effects of miglitol, an alpha-glucosidase inhibitor, on glycaemic status and histopathological changes in islets in non-obese, non-insulin-dependent diabetic Goto-Kakizaki rats.
Goda T; Suruga K; Komori A; Kuranuki S; Mochizuki K; Makita Y; Kumazawa T
Br J Nutr; 2007 Oct; 98(4):702-10. PubMed ID: 17537288
[TBL] [Abstract][Full Text] [Related]
2. Effect of miglitol, an alpha-glucosidase inhibitor, on atherogenic outcomes in balloon-injured diabetic rats.
Hirata A; Igarashi M; Iwai H; Tominaga M
Horm Metab Res; 2009 Mar; 41(3):213-20. PubMed ID: 19085811
[TBL] [Abstract][Full Text] [Related]
3. Miglitol increases the adiponectin level and decreases urinary albumin excretion in patients with type 2 diabetes mellitus.
Yokoyama H; Kannno S; Ishimura I; Node K
Metabolism; 2007 Nov; 56(11):1458-63. PubMed ID: 17950094
[TBL] [Abstract][Full Text] [Related]
4. Effect of Miglitol (Bay m1099), a new alpha-glucosidase inhibitor, on glucose, insulin, C-peptide and GIP responses to an oral sucrose load in patients with post-prandial hypoglycaemic symptoms.
Renard E; Parer-Richard C; Richard JL; Jureidini S; Orsetti A; Mirouze J
Diabete Metab; 1991; 17(3):355-62. PubMed ID: 1884880
[TBL] [Abstract][Full Text] [Related]
5. Treatment with the α-glucosidase inhibitor miglitol from the preonset stage in Otsuka Long-Evans Tokushima Fatty rats improves glycemic control and reduces the expression of inflammatory cytokine genes in peripheral leukocytes.
Mochizuki K; Fukaya N; Tanaka Y; Fuchigami M; Goda T
Metabolism; 2011 Nov; 60(11):1560-5. PubMed ID: 21550076
[TBL] [Abstract][Full Text] [Related]
6. Design and evaluation of oral bioadhesive controlled release formulations of miglitol, intended for prolonged inhibition of intestinal alpha-glucosidases and enhancement of plasma glucagon like peptide-1 levels.
Deshpande MC; Venkateswarlu V; Babu RK; Trivedi RK
Int J Pharm; 2009 Oct; 380(1-2):16-24. PubMed ID: 19563873
[TBL] [Abstract][Full Text] [Related]
7. Miglitol (BAY m 1099) treatment of diabetic hypothalamic-dietary obese rats improves islet response to glucose.
Axen KV; Li X; Sclafani A
Obes Res; 1999 Jan; 7(1):83-9. PubMed ID: 10023734
[TBL] [Abstract][Full Text] [Related]
8. The alpha-glucosidase inhibitor miglitol delays the development of diabetes and dysfunctional insulin secretion in pancreatic beta-cells in OLETF rats.
Fukaya N; Mochizuki K; Tanaka Y; Kumazawa T; Jiuxin Z; Fuchigami M; Goda T
Eur J Pharmacol; 2009 Dec; 624(1-3):51-7. PubMed ID: 19818342
[TBL] [Abstract][Full Text] [Related]
9. Effects of antihyperlipidemic agents on hepatic insulin sensitivity in perfused Goto-Kakizaki rat liver.
Matsuura B; Kanno S; Minami H; Tsubouchi E; Iwai M; Matsui H; Horiike N; Onji M
J Gastroenterol; 2004; 39(4):339-45. PubMed ID: 15168245
[TBL] [Abstract][Full Text] [Related]
10. Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki Rats.
Ueta K; Ishihara T; Matsumoto Y; Oku A; Nawano M; Fujita T; Saito A; Arakawa K
Life Sci; 2005 Apr; 76(23):2655-68. PubMed ID: 15792833
[TBL] [Abstract][Full Text] [Related]
11. The alpha-glucosidase inhibitor miglitol suppresses postprandial hyperglycaemia and interleukin-1beta and tumour necrosis factor-alpha gene expression in rat peripheral leucocytes induced by intermittent sucrose loading.
Tanaka Y; Mochizuki K; Fukaya N; Shimada M; Goda T
Br J Nutr; 2009 Jul; 102(2):221-5. PubMed ID: 19138443
[TBL] [Abstract][Full Text] [Related]
12. [Morphological changes of islet of Langerhans in an animal model of type 2 diabetes].
Seiça RM; Martins MJ; Pessa PB; Santos RM; Rosário LM; Suzuki KI; Martins MI
Acta Med Port; 2003; 16(6):381-8. PubMed ID: 15631848
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the efficacy, safety and tolerability of miglitol in adult Indian patients with uncomplicated type 2 diabetes mellitus.
Singh KP; Periyandavar I; Rajadhyaksha GC; Jayaram S; Mishra AB; Kinagi S; Sharma A; Baliga VP
J Indian Med Assoc; 2007 Jun; 105(6):344, 346, 350. PubMed ID: 18232183
[TBL] [Abstract][Full Text] [Related]
14. Insulin exocytosis in Goto-Kakizaki rat beta-cells subjected to long-term glinide or sulfonylurea treatment.
Kawai J; Ohara-Imaizumi M; Nakamichi Y; Okamura T; Akimoto Y; Matsushima S; Aoyagi K; Kawakami H; Watanabe T; Watada H; Kawamori R; Nagamatsu S
Biochem J; 2008 May; 412(1):93-101. PubMed ID: 18254725
[TBL] [Abstract][Full Text] [Related]
15. Metformin primarily decreases plasma glucose not by gluconeogenesis suppression but by activating glucose utilization in a non-obese type 2 diabetes Goto-Kakizaki rats.
Yoshida T; Okuno A; Tanaka J; Takahashi K; Nakashima R; Kanda S; Ogawa J; Hagisawa Y; Fujiwara T
Eur J Pharmacol; 2009 Nov; 623(1-3):141-7. PubMed ID: 19765581
[TBL] [Abstract][Full Text] [Related]
16. The alpha-glucosidase inhibitor miglitol decreases glucose fluctuations and gene expression of inflammatory cytokines induced by hyperglycemia in peripheral leukocytes.
Fukaya N; Mochizuki K; Shimada M; Goda T
Nutrition; 2009 Jun; 25(6):657-67. PubMed ID: 19216056
[TBL] [Abstract][Full Text] [Related]
17. The anti-diabetic drug miglitol is protective against anginal ischaemia through a mechanism independent of regional myocardial blood flow in the dog.
Uno Y; Minatoguchi S; Arai M; Wang N; Chen XH; Hashimoto K; Lu C; Takemura G; Fujiwara H
Clin Exp Pharmacol Physiol; 2005 Oct; 32(10):805-10. PubMed ID: 16173940
[TBL] [Abstract][Full Text] [Related]
18. Gene expression regulated by pioglitazone and exenatide in normal and diabetic rat islets exposed to lipotoxicity.
Ghanaat-Pour H; Sjöholm A
Diabetes Metab Res Rev; 2009 Feb; 25(2):163-84. PubMed ID: 19065603
[TBL] [Abstract][Full Text] [Related]
19. CS-917, a fructose 1,6-bisphosphatase inhibitor, improves postprandial hyperglycemia after meal loading in non-obese type 2 diabetic Goto-Kakizaki rats.
Yoshida T; Okuno A; Izumi M; Takahashi K; Hagisawa Y; Ohsumi J; Fujiwara T
Eur J Pharmacol; 2008 Dec; 601(1-3):192-7. PubMed ID: 19014931
[TBL] [Abstract][Full Text] [Related]
20. Is defective pancreatic beta-cell mass environmentally programmed in Goto-Kakizaki rat model of type 2 diabetes?: insights from crossbreeding studies during suckling period.
Calderari S; Gangnerau MN; Meile MJ; Portha B; Serradas P
Pancreas; 2006 Nov; 33(4):412-7. PubMed ID: 17079948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
